BioLineRx (BLRX) EBITDA Margin (2024 - 2025)
BioLineRx (BLRX) recorded quarterly EBITDA Margin of 1152.58% in Q4 2025, down 403.74% quarter-over-quarter from 228.81% in Q3 2025, and down 112545.0% on a YoY basis from N/an in Q4 2024.
BioLineRx (BLRX) EBITDA Margin (2024 - 2025) Analysis & Trends
BioLineRx's EBITDA Margin history runs 2 years deep, the most recent figure standing at 1152.58% for Q4 2025.
- In Q4 2025, EBITDA Margin fell 112545.0% year-over-year to 1152.58%; the TTM figure through Dec 2025 stood at 171.69% (down 13983.0% YoY), while the FY2025 annual figure was 171.69%, down 13983.0% from the prior year.
- EBITDA Margin was 1152.58% for Q4 2025 at BioLineRx, down from 228.81% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2010.59% in Q1 2025 to a low of 1296.05% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | -1,152.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,152.58% |
| Sep 30, 2025 | -228.81% |
| Jun 30, 2025 | -1,296.05% |
| Mar 31, 2025 | 2,010.59% |
| Dec 31, 2024 | -27.13% |
| Sep 30, 2024 | -126.36% |
| Jun 30, 2024 | 16.84% |
| Mar 31, 2024 | -10.15% |